Effects of perioperative hydrogen inhalation on brain edema and prognosis in patients with glioma

Abstract

Wu et al. (1) conducted a pioneering randomized controlled trial (RCT) to evaluate perioperative hydrogen inhalation in glioma patients, demonstrating a statistically significant reduction in postoperative brain edema and improved short-term neurological outcomes. While these findings highlight hydrogen’s potential as an adjuvant therapy, critical analysis from statistical and clinical perspectives is necessary to assess the validity of conclusions and guide future research. This commentary addresses methodological limitations, contextualizes the results within existing evidence on hydrogen therapy, and proposes directions for advancing this field.

Study details

Article type

Opinion / Commentary

Disease / injury model

Glioma (brain tumor) in humans

Dose-dependent effect

No

Outcome

Positive

Findings

Perioperative hydrogen inhalation in glioma patients led to a statistically significant reduction in postoperative brain edema and improved short-term neurological outcomes, but the clinical impact and long-term benefits remain to be established. The article highlights the need for larger, multicenter studies, longer follow-up, and mechanistic validation.